SCHEMBL3583365

SCHEMBL3583365

[CH2]c1ccc(N2CCN(C)CC2)c(C)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.45
ALDH1A1 P00352 5/20 0.45
KDM4E B2RXH2 3/20 0.45
RAD52 P43351 2/20 0.45
POLB P06746 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
GAA P10253 3/20 0.43
PTK2B Q14289 2/20 0.43
MEN1 O00255 1/20 0.43
THRB P10828 1/20 0.43
NR4A1 P22736 1/20 0.43
KMT2A Q03164 1/20 0.43
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
RECQL P46063 1/20 0.42
ADRA2C P18825 1/20 0.42
GFER P55789 1/20 0.41
ALDH1A3 P47895 2/20 0.41
HTR3A P46098 3/20 0.41
HTR1A P08908 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3593470 0.85 ALDH1A1 (0.43) MAPTALDH1A1KDM4ERAD52POLB
SCHEMBL7923952 0.81 HTR1A (0.58) MAPTALDH1A1POLBGAAMEN1
SCHEMBL30641872 0.78 IGF1R (0.46) MAPTALDH1A1KDM4ERAD52POLB
SCHEMBL187881 0.78 ALDH1A1 (0.71) MAPTALDH1A1KDM4ERAD52POLB
SCHEMBL29477783 0.78 ALDH1A1 (0.71) MAPTALDH1A1KDM4ERAD52POLB
SCHEMBL14922277 0.78 ALDH1A1 (0.67) MAPTALDH1A1KDM4ERAD52POLB
SCHEMBL12499570 0.78 IGF1R (0.46) MAPTALDH1A1KDM4ERAD52POLB
SCHEMBL1934165 0.78 MAPT (0.49) MAPTALDH1A1KDM4ERAD52POLB
SCHEMBL3591647 0.77 DRD2 (0.60) MAPTALDH1A1KDM4ERAD52POLB
SCHEMBL17996266 0.76 HRH3 (0.47) MAPTALDH1A1KDM4ERAD52POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029636-A1 Lck inhibitors NOVARTIS AG (CH) 2010-02-04 US disclosed
CN-101516888-A Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use NOVARTIS AG (CH) 2009-08-26 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029636-A1 Lck inhibitors LCK, ZAP70, FYN MAPT 2260/4885ALDH1A1 4236/4885KDM4E 557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.